Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$15.3 Million Settlement – Upright Builders, Inc. v. Town of Apex
Upright Builders, Inc. v. Town of Apex, Wake Co. File No. 18-CVS-3720 (NC)$15.3 million class settlement on behalf of developers and home builders for illegally charged water and sewer capacity replacement fees and transportation fees. -
See More$400+ Million Settlement – Chantix (Varenicline) Products Liability Litigation
In re Chantix (Varenicline) Products Liability Litigation, MDL 2092 (U.S. District Court for the Northern District of Alabama, Southern Division)Milberg attorneys served as Co-Lead Counsel in the Chantix Coordination in New York State Court and court-appointed member of the Plaintiffs Steering Committee in the MDL in Alabama. -
See More$1 Billion+ Trial Verdict – Vivendi Universal, S.A. Securities Litigation
In re Vivendi Universal, S.A. Securities Litigation, No. 02-CV-5571 (S.D.N.Y.)Milberg was one of two Lead Trial Counsel in this securities fraud case tried to a jury over four months in 2009-2010. The jury found Vivendi liable for dozens of false or misleading statements and awarded damages valued at well over a billion dollars. Six months later, in an unrelated case, the Supreme Court ruled that purchasers on foreign securities exchanges could not recover under U.S. law. Our case against Vivendi continued with post-verdict proceedings under the new standard, and damages have been distributed to U.S. class members totaling over $100 million. -
See More$25 Million Settlement – U.S. ex rel. Gonzales v. J.W. Carell Enterprises, Inc.
U.S. ex rel. Gonzales v. J.W. Carell Enterprises, Inc. et al., No. 12-00389 (M.D. Tn.)Milberg represented a whistleblower or “relator” in a false claims act case against one of Tennessee’s largest home healthcare providers, which alleged the company’s fraudulent submissions of Medicare and Medicaid claims. The Government intervened and the case settled in November 2014 for $25 million and the relator’s share of the settlement was $3.9 million. -
See More$138 Million Settlement – Biovail Corp. Securities Litigation
In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes.
